Adverse events
| Variable . | Ravulizumab (n = 97) . | Eculizumab (n = 98) . |
|---|---|---|
| Patients with adverse events | 85 (87.6) | 86 (87.8) |
| Most common adverse events (≥5% of patients in either treatment group) | ||
| Headache | 26 (26.8) | 17 (17.3) |
| Nasopharyngitis | 21 (21.6) | 20 (20.4) |
| Upper respiratory tract infection | 18 (18.6) | 10 (10.2) |
| Diarrhea | 9 (9.3) | 7 (7.1) |
| Pyrexia | 9 (9.3) | 5 (5.1) |
| Nausea | 8 (8.2) | 9 (9.2) |
| Constipation | 7 (7.2) | 5 (5.1) |
| Influenza-like illness | 7 (7.2) | 8 (8.2) |
| Abdominal pain | 6 (6.2) | 9 (9.2) |
| Anemia | 6 (6.2) | 3 (3.1) |
| Fatigue | 6 (6.2) | 6 (6.1) |
| Vomiting | 6 (6.2) | 4 (4.1) |
| Cough | 5 (5.2) | 10 (10.2) |
| Pain in extremity | 5 (5.2) | 4 (4.1) |
| Rhinitis | 5 (5.2) | 4 (4.1) |
| Oropharyngeal pain | 4 (4.1) | 9 (9.2) |
| Chest pain | 3 (3.1) | 9 (9.2) |
| Dizziness | 3 (3.1) | 7 (7.1) |
| Musculoskeletal pain | 2 (2.1) | 5 (5.1) |
| Dyspnea | 0 (0.0) | 6 (6.1) |
| Patients with serious adverse events | 4 (4.1) | 8 (8.2) |
| Meningococcal infections | 0 | 0 |
| Death | 0 | 0 |
| Patients with adverse events leading to withdrawal of study drug | 0 | 0 |
| Patients with serious adverse events leading to withdrawal of study drug | 0 | 0 |
| Variable . | Ravulizumab (n = 97) . | Eculizumab (n = 98) . |
|---|---|---|
| Patients with adverse events | 85 (87.6) | 86 (87.8) |
| Most common adverse events (≥5% of patients in either treatment group) | ||
| Headache | 26 (26.8) | 17 (17.3) |
| Nasopharyngitis | 21 (21.6) | 20 (20.4) |
| Upper respiratory tract infection | 18 (18.6) | 10 (10.2) |
| Diarrhea | 9 (9.3) | 7 (7.1) |
| Pyrexia | 9 (9.3) | 5 (5.1) |
| Nausea | 8 (8.2) | 9 (9.2) |
| Constipation | 7 (7.2) | 5 (5.1) |
| Influenza-like illness | 7 (7.2) | 8 (8.2) |
| Abdominal pain | 6 (6.2) | 9 (9.2) |
| Anemia | 6 (6.2) | 3 (3.1) |
| Fatigue | 6 (6.2) | 6 (6.1) |
| Vomiting | 6 (6.2) | 4 (4.1) |
| Cough | 5 (5.2) | 10 (10.2) |
| Pain in extremity | 5 (5.2) | 4 (4.1) |
| Rhinitis | 5 (5.2) | 4 (4.1) |
| Oropharyngeal pain | 4 (4.1) | 9 (9.2) |
| Chest pain | 3 (3.1) | 9 (9.2) |
| Dizziness | 3 (3.1) | 7 (7.1) |
| Musculoskeletal pain | 2 (2.1) | 5 (5.1) |
| Dyspnea | 0 (0.0) | 6 (6.1) |
| Patients with serious adverse events | 4 (4.1) | 8 (8.2) |
| Meningococcal infections | 0 | 0 |
| Death | 0 | 0 |
| Patients with adverse events leading to withdrawal of study drug | 0 | 0 |
| Patients with serious adverse events leading to withdrawal of study drug | 0 | 0 |
Values are reported as n (%) of patients.